The forces shaping markets and the economy are often hiding behind a blur of numbers.

So that's why we created The Big Take from Bloomberg Podcasts, to give you the context you need to make sense of it all.

Every day in just 15 minutes, we dive into one global business story that matters.

You'll hear from Bloomberg journalists like Matt Levine.

A lot of this meme stock stuff is, I think, embarrassing to the SEC.

Follow the Big Take podcast on the IHeart Radio app, Apple Podcasts, or wherever you listen.

Welcome to Prognosis. I'm Laura Carlson.

It's day 68 since coronavirus was declared a global pandemic.

Our main story, in discussions about reopening regions for business, there's been talk of two big prerequisites.

Testing and contact tracing.

Today, we're going to talk about the nitty-gritty of that second one. How hard contact tracing actually is, and how one country is getting it right.

But first, here's what happened today.

An experimental vaccine is showing promising results.

In a small study of a drug made by the biotech firm Moderna,

patients' immune systems were triggered to create a response to fight off the virus.

The news is reasoned for cautious optimism that the global efforts to combat the pandemic will eventually succeed. The results are just a sample from the initial study. And the small study

is designed to look at how safe it is to

inject the drug into volunteers. But the study does suggest there are no major safety worries.

That's a key hurdle to clear, since a vaccine would be given to millions of otherwise

healthy people.

Moderna is moving ahead with plans for a larger test to determine the right dose,

as well as a phase three test with many thousands of patients.

...